• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Letter by Chen et al Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Chen Chen, Dongze Li, Lixia Deng Tags: Arrhythmias, Heart Failure, Complications, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Response by Di Tullio et al to Letter Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Marco R. Di Tullio, John L.P. Thompson, Shunichi Homma, for the WARCEF Investigators Tags: Heart Failure, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 Clinical Sciences
Conclusions— In patients with atrial fibrillation, once-daily edoxaban was as effective as warfarin in preventing all strokes, with significant reductions in various subtypes of intracranial bleeding. Ischemic cerebrovascular event rates were similar with high-dose edoxaban and warfarin, whereas low-dose edoxaban was less effective than warfarin. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Giugliano, R. P., Ruff, C. T., Rost, N. S., Silverman, S., Wiviott, S. D., Lowe, C., Deenadayalu, N., Murphy, S. A., Grip, L. T., Betcher, J. M., Duggal, A., Dave, J., Shi, M., Mercuri, M., Antman, E. M., Braunwald, E., on behalf of the ENGAGE AF-TIMI 48 Tags: Other anticoagulants, Acute Cerebral Hemorrhage, Acute Cerebral Infarction, Arrhythmias, clinical electrophysiology, drugs Clinical Sciences Source Type: research

Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation Clinical Sciences
Conclusions—Upfront procedure costs initially make LAAC higher cost than warfarin and the non–vitamin K antagonist oral anticoagulants, but within 10 years, LAAC delivers more quality-adjusted life years and has lower total costs, making LAAC the most cost-effective treatment strategy for secondary prevention of stroke in atrial fibrillation.
Source: Stroke - May 25, 2018 Category: Neurology Authors: Vivek Y. Reddy, Ronald L. Akehurst, Stacey L. Amorosi, Meghan B. Gavaghan, Deanna S. Hertz, David R. Holmes Jr Tags: Atrial Fibrillation, Cost-Effectiveness Original Contributions Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation Clinical Sciences
Conclusions—In real-world practice among a high-risk Asian atrial fibrillation population, all 3 NOACs demonstrated similar risk of ischemic stroke and lower risk of ICH compared with warfarin. All-cause mortality was significantly lower only with dabigatran and apixaban.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Myung-Jin Cha, Eue-Keun Choi, Kyung-Do Han, So-Ryoung Lee, Woo-Hyun Lim, Seil Oh, Gregory Y.H. Lip Tags: Atrial Fibrillation Original Contributions Source Type: research

Female Sex, Time in Therapeutic Range, and Clinical Outcomes in Atrial Fibrillation Patients Taking Warfarin Brief Reports
Conclusion— Anticoagulated female patients with atrial fibrillation had a similar rate of cardiovascular death and SSE, but a lower risk of major bleeding, compared with males. TTR (but not female sex) was an independent predictor for combined cardiovascular death and SSE and clinically relevant bleeding events.
Source: Stroke - May 22, 2016 Category: Neurology Authors: Senoo, K., Lip, G. Y. H. Tags: Quality and Outcomes Brief Reports Source Type: research

Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? Clinical Sciences
Conclusions—There may be an obesity paradox in atrial fibrillation patients, particularly for all-cause and cardiovascular death outcomes. An obesity paradox was also evident for stroke/systemic embolic event outcome in NOAC trials, with a treatment effect favoring NOACs over warfarin for both efficacy and safety that was significant only for normal weight patients.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Marco Proietti, Elisa Guiducci, Paola Cheli, Gregory Y.H. Lip Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Obesity, Anticoagulants, Quality and Outcomes Original Contributions Source Type: research

Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS Trial Brief Reports
Conclusion— Obesity was associated with a lower stroke and mortality rate in elderly anticoagulated atrial fibrillation patients. Obesity was related to good quality anticoagulation control.
Source: Stroke - January 25, 2016 Category: Neurology Authors: Senoo, K., Lip, G. Y. H. Tags: Atrial Fibrillation, Obesity Brief Reports Source Type: research

Incidence of Symptomatic Hemorrhage in Patients With Lobar Microbleeds Clinical Sciences
Conclusions— Patients presenting with isolated lobar microbleeds on MRI have a genetic, neuroimaging, and hemorrhagic risk profile suggestive of severe CAA pathology. They have a substantial risk of incident ICH, potentially affecting decisions regarding anticoagulation in clinical situations.
Source: Stroke - July 28, 2014 Category: Neurology Authors: van Etten, E. S., Auriel, E., Haley, K. E., Ayres, A. M., Vashkevich, A., Schwab, K. M., Rosand, J., Viswanathan, A., Greenberg, S. M., Gurol, M. E. Tags: Acute Cerebral Hemorrhage, Computerized tomography and Magnetic Resonance Imaging, Intracerebral Hemorrhage, Risk Factors for Stroke, Anticoagulants Clinical Sciences Source Type: research

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin Clinical Sciences
Conclusions— In this sample of AF patients with ICB on oral anticoagulants, dabigatran was not associated with higher in-hospital mortality compared with warfarin. Hence, reluctance to use dabigatran because of a lack of approved reversal agents is not supported by our results.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Alonso, A., Bengtson, L. G. S., MacLehose, R. F., Lutsey, P. L., Chen, L. Y., Lakshminarayan, K. Tags: Cerebrovascular disease/stroke, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs, Anticoagulants Clinical Sciences Source Type: research

Rivaroxaban and Apixaban Reduce Hemorrhagic Transformation After Thrombolysis by Protection of Neurovascular Unit in Rat Basic Sciences
Conclusions— This study shows a lower risk of intracerebral hemorrhage after tissue-type plasminogen activator treatment in rats with ischemic stroke that are pretreated with rivaroxaban and apixaban compared with pretreatment with warfarin. Reducing neurovascular dissociation by rivaroxaban and apixaban compared with warfarin could partly explain a reduction in hemorrhagic complications reported in clinical studies.
Source: Stroke - July 28, 2014 Category: Neurology Authors: Kono, S., Yamashita, T., Deguchi, K., Omote, Y., Yunoki, T., Sato, K., Kurata, T., Hishikawa, N., Abe, K. Tags: Animal models of human disease Basic Sciences Source Type: research

Characteristics of Intracerebral Hemorrhage During Rivaroxaban Treatment: Comparison With Those During Warfarin Brief Reports
Conclusions— Rivaroxaban-associated ICH occurs in patients at high risk for major bleeding. However, they had a relatively small hematoma, no expansion of hematoma, and favorable functional and vital outcomes compared with warfarin-associated ICH.
Source: Stroke - August 25, 2014 Category: Neurology Authors: Hagii, J., Tomita, H., Metoki, N., Saito, S., Shiroto, H., Hitomi, H., Kamada, T., Seino, S., Takahashi, K., Baba, Y., Sasaki, S., Uchizawa, T., Iwata, M., Matsumoto, S., Osanai, T., Yasujima, M., Okumura, K. Tags: Other anticoagulants, Acute Cerebral Hemorrhage Brief Reports Source Type: research

Letter by Feng et al Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Feng, X., Huan, Y., Lv, Y. Tags: Secondary prevention, Acute Cerebral Infarction Letters to the Editor Source Type: research

Response to Letter Regarding Article, "Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control" Letters to the Editor
Source: Stroke - February 23, 2015 Category: Neurology Authors: Chan, P.-H., Hai, J. J., Siu, C.-W. Tags: Coumarins Letters to the Editor Source Type: research

Do Patient Characteristics Explain the Differences in Outcome Between Medically Treated Patients in SAMMPRIS and WASID? Clinical Sciences
Conclusions— After adjustment for confounding baseline characteristics, WASID patients had an almost 2-fold higher risk of the SAMMPRIS primary end point, which supports the hypothesis that the lower rate of the primary end point in the medical arm of SAMMPRIS compared with WASID patients was as a result of the aggressive medical management used in SAMMPRIS. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00576693.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Chaturvedi, S., Turan, T. N., Lynn, M. J., Derdeyn, C. P., Fiorella, D., Janis, L. S., Chimowitz, M. I., for the SAMMPRIS Trial Investigators Tags: Risk Factors Clinical Sciences Source Type: research

Pages: 1  2  3  4  5  6